Academy of Military Medical Sciences
The Academy of Military Medical Sciences (AMMS) of the PLA Academy of Military Science (Chinese: 中国人民解放军军事科学院军事医学研究院) is a Chinese military medical research institute.[1][2] It was established in Shanghai in 1951.[3] It has been based in Beijing since 1958.
Academy of Military Medical Sciences | |||||||
---|---|---|---|---|---|---|---|
Simplified Chinese | 中国人民解放军军事科学院军事医学研究院 | ||||||
Traditional Chinese | 中國人民解放軍軍事科學院軍事醫學研究院 | ||||||
|
In October 2011 the drug "Night Eagle", developed to help soldiers cope with sleep deprivation during missions, was unveiled in an exhibition marking the institute's 60th anniversary.[4]
In December 2014, the Chinese government announced that the Academy of Military Medical Sciences had developed an Ebola virus vaccine candidate that had been approved for clinical trials.[1][2]
COVID-19 vaccine
During the COVID-19 pandemic, the AMMS partnered with CanSino Biologics to develop a COVID-19 vaccine. The development team, led by Chen Wei, registered an experimental COVID-19 vaccine for Phase 1 trial on 17 March 2020 to test its safety. The vaccine was tried on 108 healthy volunteers in Wuhan. In April 2020, the vaccine entered Phase 2 to test its effectiveness on 500 volunteers.[5][6] The vaccine was the first one approved outside of clinical trials in an expedite decision, which authorized its use only by the Chinese military.[7]
See also
- Wu Dechang, radiation toxicologist and former President of AMMS
- JK-05
References
- "China's Ebola vaccine enters clinical trials". Retrieved 19 December 2014.
- "China approves experimental Ebola vaccine for clinical trials". Reuters. 18 December 2014. Retrieved 19 December 2014.
- Patti Waldmeir (October 15, 2014). "China sends thousands of doses of anti-Ebola drug to Africa". Financial Times.
- "PLA eyes 'Night Eagle' to make army of night owls". South China Morning Post. 16 October 2011. Retrieved 5 January 2017.
- Xie, John (15 April 2020). "China Announces Phase 2 of Clinical Trials of COVID-19 Vaccine". Voice of America. Retrieved 18 April 2020.
- "The Lancet: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response". EurekAlert!. 22 May 2020. Retrieved 24 December 2020.
- "CanSino's COVID-19 vaccine candidate approved for military use in China". Reuters (in Portuguese). 2020-06-29. Retrieved 2020-07-01.